Background: Whether all types of inhaled corticosteroids (ICSs) would increase the
pneumonia risk in patients with chronic obstructive pulmonary disease (COPD) remains …

Background Bronchiectasis is being increasingly diagnosed and recognised as an important
contributor to chronic lung disease in both adults and children in high‐and low‐income …

Objective Inhaled corticosteroids (ICS) are generally used to treat patients with chronic
obstructive pulmonary disease (COPD) who suffer from repeated exacerbations. Recently, it …

Background Inhaled corticosteroids (ICSs) have been used widely in the maintenance
therapy of COPD. However, whether inhaled therapy containing ICSs can reduce the all …

Background Inhaled corticosteroids (ICS) are associated with an increased risk of
pneumonia in patients with chronic obstructive pulmonary disease (COPD). Other factors …

Bronchiectasis is characterized by systemic inflammation and multiple comorbidities. This
study aimed to investigate the clinical outcomes based on the bronchiectasis etiology …

Abstract Chronic Obstructive Pulmonary Disease (COPD) is among the leading causes of
morbidity and mortality in developing countries; however, few systematic reviews are …

Triple inhaled therapy for chronic obstructive pulmonary disease (COPD) consists of an
inhaled corticosteroid (ICS), a long-acting β2-agonist (LABA) and a long-acting muscarinic …

Background Despite multiple available fixed-dose combinations (FDCs) of inhaled long-
acting β 2-agonists (LABAs) plus long-acting muscarinic antagonists (LAMAs) and LABAs …

Rationale: Inhaled corticosteroids (ICS) are established medications for the management of
both asthma and chronic obstructive pulmonary disease (COPD), two common chronic …